

Synthetic Methods

Solid-Phase Peptide Macrocyclization and Multifunctionalization via Dipyrrin Construction

Yue Wu, Ho-Fai Chau, Waygen Thor, Kaitlin Hao Yi Chan, Xia Ma, Wai-Lun Chan,*
Nicholas J. Long,* and Ka-Leung Wong*

Abstract: We introduce a new and highly efficient synthetic protocol towards multifunctional fluorescent cyclopeptides by solid-phase peptide macrocyclization via dipyrrin construction, with full scope of proteinogenic amino acids and different ring sizes. Various bicyclic peptides can be created by dipyrrin-based crosslinking and double dipyrrin-ring formation. The embedded dipyrrin can be either transformed to fluorescent BODIPY and then utilized as cancer-selective targeted protein imaging probe *in vitro*, or directly employed as a selective metal sensor in aqueous media. This work provides a valuable addition to the peptide macrocyclization toolbox, and a blueprint for the development of multifunctional dipyrrin linkers in cyclopeptides for a wide range of potential bioapplications.

Conformationally constrained macrocyclic peptides^[1] possessing larger target-selective binding surfaces of higher affinity,^[2] ameliorated cell permeability and stability,^[3,4] and versatile and remarkable pharmacological properties^[5] compared with their linear counterparts have emerged as novel and promising molecular platforms for efficaciously modulating disease-relevant protein–protein interactions (PPIs)—known therapeutic targets or those previously thought to be “undruggable”.^[6] To this end, a repertoire of peptide macrocyclization and stapling approaches has been developed and diversified over the past decade.^[7] Cross-couplings,^[8] click reactions,^[9] C–H activations/functionalizations,^[10] ring-closing olefin metathesis reactions,^[11] Diels–Alder cycloaddi-

tions,^[12] multicomponent Ugi/Petasis-type reactions,^[13] and ligation-mediated cyclizations,^[14] among others,^[15] have been established in site-specific fashions employing a variety of anchoring residues/terminal groups.^[16] New structural–functional moieties can be introduced into the backbones of peptide macrocycles via certain above-mentioned approaches as the staple linkers, which can be manipulated to optimize the cyclopeptide ring size/rigidity, and furnish new handling sites for small-molecule drug and fluorescent dye conjugations to access unprecedented chemotypes and become powerful tools to probe PPIs and orchestrate therapeutic applications.^[17]

Although monofunctional modifiable staple linkers as “triotopic connectors” have been well-reported, (Figure 1a) other strategic functional designs and applications still remain underexplored. For luminescent staple linkers, Fei et al. have reported a luminogenic peptide stapling strategy utilizing bis(histidine)–iridium(III) complex coordination chemistry with RGD and oligoarginine peptides for cancer cell targeting, imaging and killing.^[18,19] Perrin et al. have realized a mild, metal-free, and late-stage fluorescent isoindole crosslink strategy by employing phthalaldehyde-mediated “isoindole intramolecular stapling” chemoselectively with peptides’ amine–thiol groups, where the isoindole can serve as a fluo-

[*] Y. Wu, H.-F. Chau, W. Thor, K. H. Y. Chan, X. Ma, Prof. Dr. K.-L. Wong
Department of Chemistry, Hong Kong Baptist University
Kowloon Tong, Kowloon, Hong Kong SAR (China)
E-mail: klwong@hkbu.edu.hk


K. H. Y. Chan, Dr. W.-L. Chan
Department of Applied Biology and Chemical Technology
Hong Kong Polytechnic University
Hung Hom, Hong Kong SAR (China)
E-mail: wai-lun-kulice.chan@polyu.edu.hk

Prof. Dr. N. J. Long
Department of Chemistry, Imperial College London
Molecular Sciences Research Hub
London (UK)
E-mail: n.long@imperial.ac.uk


Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/anie.202108885>.

© 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

a. Conventional Modifiable Staple Linkers (many examples)



b. Functional Staple Linkers (limited examples)



c. Multifunctional Dipyrrin Staple Linker (this work)





Figure 1. Contemporary examples of functional staple linkers in cyclic peptides. a) Structurally modifiable staple linkers for further ligations of fluorescent dyes and targeting vectors; b) functional staple linkers as the luminophore, the catalytic center, and the photoswitch/photocontrol; c) our new multifunctional dipyrrin staple linker for targeted BODIPY imaging and selective zinc sensing.

rophore.^[20] On the other hand, through installing photo-responsive azobenzene,^[21] by Gorostiza et al., or photocleavable *s*-tetrazine staple linkers,^[22] by Smith et al., precision optical modulations of stapled peptides for “off-on” inhibition and unstapling have also been feasible (Figure 1 b). For a catalytic linker, Mascareñas et al. realized the first “stapled pallado-miniprotein”-promoted depropargylation reaction in live cells.^[23] To develop new multifunctional staple linkers for de novo macrocyclic/stapled peptide design for both medicinal and bioanalytical chemistry purposes, more advances in cyclization/coupling reactions and their translational applications into cyclopeptide syntheses, functionalizations and modifications are urgently needed.

Very recently, our group has disclosed a facile, efficient, and purification-economical Fmoc-based solid-phase synthetic method for fluorescent boron-dipyrromethene

(BODIPY)-peptide conjugates via in situ dipyrryn construction.^[24] We then speculated that such solid-phase dipyrryn assembly reaction can also be compatibly utilized for peptide macrocyclization and stapling, i.e., the dipyrryn as a new multifunctional staple linker, to obtain highly sought-after either fluorescent BODIPY-containing, or metal-chelating thus light-emissive macrocyclic peptides. Herein, we unleash the potential of a new multi-functional dipyrryn staple linker and introduce our solid-phase peptide macrocyclization and multifunctionalization strategy via dipyrryn coupling and manipulation (Figure 1c). Broad substrate scopes (i.e., amino acids and the *meso* position of dipyrryn) of the reaction are substantiated, while enhanced stabilities and higher selective target binding affinities of the resulting dipyrryn-cyclopeptides than their linear counterparts are corroborated. Various bicyclic peptides can also be formed by dipyrryn-

a. Different methods to introduce the *meso* bridge of dipyrryn on the GHK peptide



b. Constructing dipyrryn on different peptide chains




Figure 2. Formation of dipyrryn cyclopeptides. Percent conversions were reported and determined by HPLC. a) The synthetic routes for dipyrryn-GHK cyclopeptides, where the dipyrryn linker can be constructed by Methods A/B for the scope of *meso* bridge. b) The synthetic routes for constructing dipyrryn on different peptide chains containing two pyrrolyl groups, incorporating all proteinogenic amino acids of different ring sizes by Method A^a and/or Method B^b.

based crosslinking and bicyclization. With the cyclic RGD and GHK peptide backbones, the dipyrin staple linker can be either transformed to fluorescent BODIPY and then utilized for bladder cancer cell (T24)-selective targeted $\alpha_v\beta_3$ integrin probe, or directly employed as a selective zinc(II) sensor in aqueous media (detection limit = 4.37 nM). This work provides a practical addition to the reaction toolbox available for accessing peptide macrocycles, with dipyrins being multifunctional staple linkers.

To construct our proposed cyclopeptides cyclized by the dipyrin moiety, we initiated the study of dipyrin-directed peptide macrocyclization methodology with the GHK peptide sequence, based on the FDA-approved drug preztatide, as the first trial. As shown in Figure 2a, the commercially available COOH-containing pyrrole building block, 3-(2,4-dimethyl-1*H*-pyrrol-3-yl)propanoic acid, was efficiently coupled onto two amine groups (N-terminus and/or side chain of lysine) on the resin-bound GHK under solid-phase conditions. Upon systematic screening, Methods A and B were discovered and strategically optimized for introducing various alkyl and aromatic moieties at the *meso* position of the formed dipyrins. The commercially available orthoesters were used for constructing dipyrins with hydrogen, methyl or ethyl groups at the *meso* position effectively (Method A, **1a–1c**) with the aid of POCl₃ in CH₂Cl₂. With our previously established protocol,^[24] the two pyrroles on-resin can be condensed with various commercially available aldehydes

(e.g., polarity-sensitive pyrene and AIEgen tetraphenyl-ethene) under the catalysis of BF₃·OEt₂ in DMF, and the resulting dipyrin-cyclopeptides could be obtained with high percent conversions (all > 80%) after DDO oxidation and global cleavage and deprotection (Method B, **1d–1h**). In essence, when 4-carboxybenzaldehyde was used, COOH-containing dipyrin cyclopeptide could be obtained (**1h**) with very high percent conversion (94%), and continued SPPS with it afforded **1i** to have an additional peptide chain, which may accomplish other functions or serve as anchors for further manipulations.

We then adopted these methods on a series of other peptide chains (Figure 2b) to yield **2** (GAK peptide), **4a–4d** (XRGD peptides, where X are amino acid residues with amines on their side chain in different lengths for screening a suitable $\alpha_v\beta_3$ -targeting RGD cyclic peptide), **5** (derived from FDA-approved cyclic peptide drug Bremelanotide), **6, 7**, and **8** (derived from ATSP-6935, a P53-targeting cyclic peptide under clinical trial), all in reasonable conversions (~30–70%). Both head-to-side chain and side chain-to-side chain cyclizations could be performed with different ring sizes (containing 3–8 residues) and 20 standard proteinogenic amino acids had been proved to be compatible with both Methods A and B. We further strove for some special cases with our methods (Figure 3). The bridged bicyclic product **9** (Figure S5, S6) was obtainable by Method B with 4-carboxybenzaldehyde followed by intramolecular amidation (49%




Figure 3. Special cases: bicyclic product **9**, "interbranch"-coupled product **10**, and double-dipyrin cyclic peptide **11**. Percent conversions were reported and determined by HPLC.

percent conversion). When Method A was carried out on a RGD peptide with only one amine group, “interbranch” coupling happened to create the dipyrin-bis(RGD)-peptide conjugate **10** (Figure S7) in $\approx 70\%$ percent conversion. In particular, we achieved a head-to-side chain and a side chain-to-side chain dipyrin cyclic linker on the same peptide chain to afford double-cyclic **11** (Figure S8, S9) in a stepwise manner in 30% conversion.

RGD peptides are known for their preferential binding to the $\alpha_v\beta_3$ integrin,^[25] which is overexpressed in bladder cancer cells.^[26] With the new structures of dipyrin-embedded cyclic RGD (cRGD) peptides (**4a–4d**) secured by our new synthetic methodology, we next evaluated their protease resistance, analyzed their conformation, examined their selective $\alpha_v\beta_3$ binding affinity, and measured their photophysics upon further BODIPY transformation in order to develop them as new fluorescent cyclopeptide-based targeted $\alpha_v\beta_3$ probes as a model case study. A protease stability assay, with trypsin at 37°C, was conducted for both **3a** (linear KRGDK peptide as the control, Figure S3) and **4a** (cyclic dipyrin-embedded KRGDK peptide). The assay results showed that **3a** was decomposed completely within 30 min, while around 60% of **4a** still survived after 240 min (Figure 4a), thereby proving the far higher protease resistance of cyclic **4a** than the linear **3a**. Circular dichroism (CD) measurements were performed,

at 25°C, to analyze if there would be any conformational differences between the linear **3a–3d** (Figure S3 and S4) and cyclic **4a–4d**, and random coiled structures of all of them were demonstrated, with the shape of peak signals of the cyclic samples being more obvious (Figure S19). The $\alpha_v\beta_3$ binding competitive displacement assay^[27] was carried out with cyclic **4a–4d**, linear **3a**, and the positive control cilengitide (a commercially available cyclic RGDfV peptide selectively targeting $\alpha_v\beta_3$) and the result validated that **4b** showed a higher binding affinity than **4a**, **4c–4d**, as well as its linear version **3b** (Figure 4b). Molecular docking was also conducted for **3a–3d** and **4a–4d**; all of them overlapped with the RGD motif of fibronectin (Figure S21–S23, the native ligand in the crystal structure of $\alpha_v\beta_3$) with the estimated binding energies in the order of **4b** > **4a/4c** > **4d** > **3a–3d** that accorded well with the result of a binding affinity assay (Table S6). Therefore, boron complexation was implemented on **4b** to convert it into the corresponding BODIPY-embedded cyclo-XRGDX-peptide **4b-BODIPY** (X = Orn, Figure 4c) with bright fluorescence (quantum yield (Φ) = 0.93; lifetime (τ) = 7.1 ns, Figure 4d). We performed confocal in vitro imaging for **4b-BODIPY** with $\alpha_v\beta_3$ -overexpressed bladder cancer T24 cell lines, as well as the negative control normal MRC5 and cervical cancer HeLa cell lines (Figure 4e). Both **4b-BODIPY** (green) and the fluorescent $\alpha_v\beta_3$ specific antibody (red) displayed good preferential cellular uptake and excellent signal overlapping in T24 cell lines, but not in the others. This indicated the great potential of **4b-BODIPY** as a fluorescent cyclopeptide-based targeted $\alpha_v\beta_3$ probe^[28] whose fluorescence comes from the BODIPY staple linker.

In addition, GHK peptide and dipyrin are well-known moieties to chelate with zinc(II) ions;^[29] we were then interested to see if **1a** (of cyclic GHK peptide, cGHK) could be employed as a new potential fluorescent Zn^{2+} sensor. Impressively, **1a** exhibited a highly sensitive and selective response toward Zn^{2+} over a wide range of dications in aqueous media as fluorescence intensity increased over 130-fold upon the addition of Zn^{2+} (Figure 5 a,b, Video S1). The stoichiometry between **1a** and Zn^{2+} was determined as 1:1 by Job's plot (Figure S13). The detection limit of $1\ \mu\text{M}$ **1a** toward Zn^{2+} was calculated to be 4.37 nM (Figure S12), while the quantum yield of **1a** with saturated Zn^{2+} was recorded to be 0.31. No significant temperature effect (at 0°C, 25°C and 37°C) was found towards **1a**'s emission intensity (Figure S14); **1a** functioned pretty well under basic conditions (pH 7–11) but not under acidic conditions (pH < 6.5, Figure S15). To better understand **1a**'s zinc binding ability and sensing mechanism, we measured the binding constant of **1a** with Zn^{2+} in HEPES buffer, which was found to be $1.418 \times 10^6\ \text{M}^{-1}$, a value of not so strong binding. Therefore, the fluorescence could be quenched by addition of DTPA, a strong metal chelator. On the other hand, fluorescence Zn^{2+} titrations were also performed for *meso*-substituted **1b** and **1d**, GAK-based variant **2**, as well as the linear analogue **8**, and none of them manifested a performance as good as **1a**'s. For **1b** and **1d**, with the methyl/phenyl substitution on the *meso* position, they showed very faint fluorescence over the titration,^[30] despite showing similar binding constants with




Figure 4. Dipyrrin/BODIPY-embedded cRGD peptides as potential $\alpha_v\beta_3$ probe. a) In vitro trypsin resistance assays for cyclic **4a** versus linear **3a** at 37°C. b) $\alpha_v\beta_3$ binding assay of cyclic **4a–d**, linear **3a**, and the positive control cilengitide. c) The structures of BODIPY-embedded cyclopeptides **4b-BODIPY**. d) The normalized excitation/emission spectra of **4b-BODIPY** in HEPES buffer, with the quantum yield (Φ) = 0.93 and the lifetime (τ) = 7.1 ns. e) Confocal imaging of 10 μm **4b-BODIPY** (green) and fluorescent $\alpha_v\beta_3$ -specific antibody (red) in T24, MRC5, and HeLa cell lines. Error bars represent the standard deviation of the mean.




Figure 5. Dipyrin-embedded cGHK peptide **1a** as a selective Zn^{2+} sensor in aqueous buffer HEPES. a) The fluorescence titration of **1a** with Zn^{2+} . b) The fluorescent responses of **1a** toward various metal ions. c) The changes in NMR spectrum of **1a** upon the addition of $\text{Zn}(\text{OAc})_2$.

Zn^{2+} as **1a** (Figure S16). The dipyrin-embedded GAK cyclopeptide **2** missing the imidazole side chain also illustrated over 100-fold enhancement as the addition of excess Zn^{2+} ; however, its sensitivity was proved far poorer than **1a**'s, with its binding constant being $\approx 1/50$ of that of **1a** (Figure S17). For the linear analogue of dipyrin-attached GHK peptide conjugate **S6** (Figure S10), its binding constant was found to lie in between that of **1a** and **2** (Figure S18). All these findings substantiated that the unique scaffold of dipyrin-embedded cGHK peptide and the presence of imidazole group were crucial for the serendipitous Zn^{2+} chelating and sensing properties of **1a**. The binding between **1a** and Zn^{2+} was then monitored by NMR titration (Figure 5c). Upon the addition of Zn^{2+} salt, both the signal of imidazole-NH and dipyrin-NH were decreased/broadened simultaneously, which indicated the zinc atom had bound to imidazole-NH and dipyrin-NH at the same time. The two imidazole-CH were also found shifting during the titration, while other signals remained unchanged.

In summary, we report a new and highly efficient solid-phase synthetic methodology towards multifunctional fluorescent cyclic peptides of broad amino acid scope and varying

ring size via dipyrin coupling-driven head-to-side chain and side chain-to-side chain peptide macrocyclization, where the resulting dipyrin serves as a new multifunctional staple linker. Various complex bicyclic peptide structures can be obtained; in two of our models, with the cyclic RGD and GHK peptide backbones, the embedded dipyrin can be, respectively, either transformed to fluorescent BODIPY (**4b-BODIPY**) and then utilized as a bladder cancer cell (T24)-selective targeted $\alpha_v\beta_3$ integrin probe in vitro, or directly employed as a selective zinc(II) sensor (**1a**) in aqueous media. From these first-generation multifunctional fluorescent cyclopeptides (**4b-BODIPY** and **1a**), insights have been gained for the importance of the linker length of the cyclic peptide scaffold as well as the presence of donor side chain as multidentate ligand. This work provides a valuable addition to the peptide macrocyclization-multifunctionalization toolbox and empowers the further development of multifunctional dipyrin-cyclopeptides for multifarious bioapplications.

Acknowledgements

This work was supported by grants from the Hong Kong Research Grant Council (HKBU 12300320), CAS-Croucher Funding Scheme for Joint Laboratories (CAS 18204), UGC Research Matching Grant Scheme (NLMT and HKBU Joint Lab for Combating Prostate Cancer), and the Hong Kong Polytechnic University (Start-up Fund for RAPs under the Strategic Hiring Scheme P0035714). N.J.L. is grateful for a Royal Society Wolfson Merit Award and for the Dr Kennedy Wong Distinguished Visiting Professorship at Hong Kong Baptist University. K.L.W. acknowledges Dr. Mok Man Hung Endowed Professorship in Chemistry at Hong Kong Baptist University. The University Research Facility in Life Sciences (ULS) at the Hong Kong Polytechnic University is also gratefully acknowledged.

Conflict of Interest

The authors declare no conflict of interest.

Keywords: dipyrin · fluorescent cyclic peptides · solid-phase peptide synthesis · zinc(II) sensing · $\alpha_v\beta_3$ imaging

- [1] For selected recent reviews, see: a) K. Bozovičar, T. Bratkovič, *Int. J. Mol. Sci.* **2021**, *22*, 1611; b) R. González-Muñiz, M. Á. Bonache, M. J. Pérez de Vega, *Molecules* **2021**, *26*, 445; c) M. T. J. Bluntzer, J. O'Connell, T. S. Baker, J. Michel, *Pept. Sci.* **2020**, *113*, e24191; d) A. V. Vinogradov, Y. Yin, H. Suga, *J. Am. Chem. Soc.* **2019**, *141*, 4167–4181; e) A. M. Ali, J. Atmaj, N. V. Oosterwijk, M. R. Groves, A. Dömling, *Comput. Struct. Biotechnol. J.* **2019**, *17*, 263–281; f) T. A. Hill, N. E. Shepherd, F. Diness, D. P. Fairlie, *Angew. Chem. Int. Ed.* **2014**, *53*, 13020–13041; *Angew. Chem.* **2014**, *126*, 13234–13257.
- [2] For selected representative works, see: a) T. E. Speltz, S. W. Fanning, C. G. Mayne, C. Fowler, E. Tajkhorshid, G. L. Greene, T. W. Moore, *Angew. Chem. Int. Ed.* **2016**, *55*, 4252–4255; *Angew. Chem.* **2016**, *128*, 4324–4327; b) O. V. Maltsev, U. K. Marelli, T. G. Kapp, F. S. Di Leva, S. Di Maro, M. Nieberler, U.

- Reuning, M. Schwaiger, E. Novellino, L. Marinelli, H. Kessler, *Angew. Chem. Int. Ed.* **2016**, *55*, 1535–1539; *Angew. Chem.* **2016**, *128*, 1559–1563.
- [3] For a recent review, see: a) P. G. Dougherty, A. Sahni, D. Pei, *Chem. Rev.* **2019**, *119*, 10241–10287; For a selected work, see: b) L. Peraro, Z. Zou, K. M. Makwana, A. E. Cummings, H. L. Ball, H. Yu, Y.-S. Lin, B. Levine, J. A. Kritzer, *J. Am. Chem. Soc.* **2017**, *139*, 7792–7802.
- [4] For a selected work, see: G. H. Bird, N. Madani, A. F. Perry, A. M. Princiotta, J. G. Supko, X. He, E. Gavathiotis, J. G. Sodroski, L. D. Walensky, *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 14093–14098.
- [5] For selected recent works on cyclopeptides with remarkable bioactivities, see: a) S. Wu, Y. He, X. Qiu, W. Yang, W. Liu, X. Li, Y. Li, H.-M. Shen, R. Wang, Z. Yue, Y. Zhao, *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E5669–E5678; b) C. M. Faden, J. M. Wolfe, C.-F. Cho, A. Chiocca, S. E. Lawler, B. L. Pentelute, *J. Am. Chem. Soc.* **2017**, *139*, 15628–15631; c) A. Kuster, N. L. Mozafari, O. J. Wilkinson, J. L. Wojtaszek, C. Zurfluh, S. Przetocka, D. Zyla, C. von Aesch, M. S. Dillingham, R. S. Williams, A. A. Sartori, *Sci. Adv.* **2021**, *7*, eabc6381; d) X. Chen, J. Fu, F. Zhou, Q. Yang, J. Wang, H. Feng, W. Jiang, L. Jin, X. Tang, N. Jiang, J. Yin, J. Han, *J. Med. Chem.* **2020**, *63*, 12595–12613; e) S. Mitra, J. E. Montgomery, M. J. Kolar, G. Li, K. J. Jeong, B. Peng, G. L. Verdine, G. B. Mills, R. E. Moellering, *Nat. Commun.* **2017**, *8*, 660; f) Y. S. Chang, B. Graves, V. Guerlavais, C. Tovar, K. Packman, K.-H. To, K. A. Olson, K. Kesavan, P. Gangurde, A. Mukherjee, T. Baker, K. Darlak, C. Elkin, Z. Filipovic, F. Z. Qureshi, H. Cai, P. Berry, E. Feyfant, X. E. Shi, J. Horstick, D. Allen Annis, A. M. Manning, N. Fotouhi, H. Nash, L. T. Vassilev, T. K. Sawyer, *Proc. Natl. Acad. Sci. USA* **2013**, *110*, E3445–E3454.
- [6] For selected recent reviews, see: a) L. Nevola, E. Giralt, *Chem. Commun.* **2015**, *51*, 3302–3315; b) N. Tsomaia, *Eur. J. Med. Chem.* **2015**, *94*, 459–470.
- [7] For selected reviews, see: a) C. J. White, A. K. Yudin, *Nat. Chem.* **2011**, *3*, 509–524; b) Y. H. Lau, P. de Andrade, Y. Wu, D. R. Spring, *Chem. Soc. Rev.* **2015**, *44*, 91–102.
- [8] For selected recent works, see: a) K. Kubota, P. Dai, B. L. Pentelute, S. L. Buchwald, *J. Am. Chem. Soc.* **2018**, *140*, 3128–3133; b) M. Ben-Lulu, E. Gaster, A. Libman, D. Pappo, *Angew. Chem. Int. Ed.* **2020**, *59*, 4835–4839; *Angew. Chem.* **2020**, *132*, 4865–4869.
- [9] For a selected recent work, see: Y. H. Lau, Y. Wu, M. Rossmann, B. X. Tan, P. de Andrade, Y. S. Tan, C. Verma, G. J. McKenzie, A. R. Venkitaraman, M. Hyvönen, D. R. Spring, *Angew. Chem. Int. Ed.* **2015**, *54*, 15410–15413; *Angew. Chem.* **2015**, *127*, 15630–15633.
- [10] For selected recent works, see: a) L. Mendive-Tapia, S. Preciado, J. García, R. Ramón, N. Kielland, F. Albericio, R. Lavilla, *Nat. Commun.* **2015**, *6*, 7160; b) A. F. M. Noisier, J. García, I. A. Ionuț, F. Albericio, *Angew. Chem. Int. Ed.* **2017**, *56*, 314–318; *Angew. Chem.* **2017**, *129*, 320–324; c) M. M. Lorion, N. Kaplaneris, J. Son, R. Kuniyil, L. Ackermann, *Angew. Chem. Int. Ed.* **2019**, *58*, 1684–1688; *Angew. Chem.* **2019**, *131*, 1698–1702; d) N. Kaplaneris, T. Rogge, R. Yin, H. Wang, G. Sirvinskaite, L. Ackermann, *Angew. Chem. Int. Ed.* **2019**, *58*, 3476–3480; *Angew. Chem.* **2019**, *131*, 3514–3518; e) X. Zhang, G. Lu, M. Sun, M. Mahankali, Y. Ma, M. Zhang, W. Hua, Y. Hu, Q. Wang, J. Chen, G. He, X. Qi, W. Shen, P. Liu, G. A. Chen, *Nat. Chem.* **2018**, *10*, 540–548; f) B. Li, X. Li, B. Han, Z. Chen, X. Zhang, G. He, G. Chen, *J. Am. Chem. Soc.* **2019**, *141*, 9401–9407; g) Z. Bai, C. Cai, W. Sheng, Y. Ren, H. Wang, *Angew. Chem. Int. Ed.* **2020**, *59*, 14686–14692; *Angew. Chem.* **2020**, *132*, 14794–14800.
- [11] For selected recent works, see: a) G. J. Hilinski, Y.-W. Kim, J. Hong, P. S. Kutchukian, C. M. Crenshaw, S. S. Berkovitch, A. Chang, S. Ham, G. L. Verdine, *J. Am. Chem. Soc.* **2014**, *136*, 12314–12322; b) S. L. Mangold, D. J. O’Leary, R. H. Grubbs, *J. Am. Chem. Soc.* **2014**, *136*, 12469–12478; c) C. Xu, X. Shen, A. H. Hoveyda, *J. Am. Chem. Soc.* **2017**, *139*, 10919–10928.
- [12] J. E. Montgomery, J. A. Donnelly, S. W. Fanning, T. E. Speltz, X. Shangguan, J. S. Coukos, G. L. Greene, R. E. Moellering, *J. Am. Chem. Soc.* **2019**, *141*, 16374–16381.
- [13] For a selected recent review, see: a) L. Reguera, D. G. Rivera, *Chem. Rev.* **2019**, *119*, 9836–9860; for selected representative works, see: b) M. G. Ricardo, A. M. Ali, J. Plewka, E. Surmiak, B. Labuzek, C. G. Neochoritis, J. Atmaj, L. Skalniak, R. Zhang, T. A. Holak, M. Groves, D. G. Rivera, A. Dömling, *Angew. Chem. Int. Ed.* **2020**, *59*, 5235–5241; *Angew. Chem.* **2020**, *132*, 5273–5279; c) M. G. Ricardo, D. Llanes, L. A. Wessjohann, D. G. Rivera, *Angew. Chem. Int. Ed.* **2019**, *58*, 2700–2704; *Angew. Chem.* **2019**, *131*, 2726–2730; d) A. Yamaguchi, S. J. Kaldas, S. D. Appavoo, D. B. Diaz, A. K. Yudin, *Chem. Commun.* **2019**, *55*, 10567–10570; e) M. C. Morejón, A. Laub, B. Westermann, D. G. Rivera, L. A. Wessjohann, *Org. Lett.* **2016**, *18*, 4096–4099; f) A. V. Vasco, C. S. Pérez, F. E. Morales, H. E. Garay, D. Vasilev, J. A. Gavín, L. A. Wessjohann, D. G. Rivera, *J. Org. Chem.* **2015**, *80*, 6697–6707; g) M. G. Ricardo, F. E. Morales, H. Garay, O. Reyes, D. Vasilev, L. A. Wessjohann, D. G. Rivera, *Org. Biomol. Chem.* **2015**, *13*, 438–446.
- [14] For a selected recent review, see: H. Y. Chow, Y. Zhang, E. Matheson, X. Li, *Chem. Rev.* **2019**, *119*, 9971–10001.
- [15] For a selected recent review, see: a) D. G. Rivera, G. M. Ojeda-Carralero, L. Reguera, E. V. Van der Eycken, *Chem. Soc. Rev.* **2020**, *49*, 2039–2059; for selected representative works, see: b) Y. Zhang, Q. Zhang, C. T. T. Wong, X. Li, *J. Am. Chem. Soc.* **2019**, *141*, 12274–12279; c) L. R. Malins, J. N. de Gruyter, K. J. Robbins, P. M. Scola, M. D. Eastgate, M. Reza Ghadiri, P. S. Baran, *J. Am. Chem. Soc.* **2017**, *139*, 5233–5241; d) G. Lautrette, F. Touti, H. G. Lee, P. Dai, B. L. Pentelute, *J. Am. Chem. Soc.* **2016**, *138*, 8340–8343; e) A. Bandyopadhyay, J. Gao, *J. Am. Chem. Soc.* **2016**, *138*, 2098–2101; f) B. Li, H. Tang, A. Turlik, Z. Wan, X.-S. Xue, L. Li, X. Yang, J. Li, G. He, K. N. Houk, G. Chen, *Angew. Chem. Int. Ed.* **2021**, *60*, 6646–6652; *Angew. Chem.* **2021**, *133*, 6720–6726; g) J. Ceballos, E. Grinhagena, G. Sangouard, C. Heinis, J. Waser, *Angew. Chem. Int. Ed.* **2021**, *60*, 9022–9031; *Angew. Chem.* **2021**, *133*, 9104–9113; h) M. J. S. A. Silva, H. Faustino, J. A. S. Coelho, M. V. Pinto, A. Fernandes, I. Compañón, F. Corzana, G. Gasser, P. M. P. Gois, *Angew. Chem. Int. Ed.* **2021**, *60*, 10850–10857; *Angew. Chem.* **2021**, *133*, 10945–10952; i) V. Adebomi, R. D. Cohen, R. Wills, H. A. H. Chavers, G. E. Martin, M. Raj, *Angew. Chem. Int. Ed.* **2019**, *58*, 19073–19080; *Angew. Chem.* **2019**, *131*, 19249–19256; j) L. Raynal, N. C. Rose, J. R. Donald, C. D. Spicer, *Chem. Eur. J.* **2021**, *27*, 69–88; k) Y. Wang, D. H.-C. Chou, *Angew. Chem. Int. Ed.* **2015**, *54*, 10931–10934; *Angew. Chem.* **2015**, *127*, 11081–11084; l) R. Morewood, C. Nitsche, *Chem. Sci.* **2021**, *12*, 669–674.
- [16] X. Li, S. Chen, W.-D. Zhang, H.-G. Hu, *Chem. Rev.* **2020**, *120*, 10079–10144.
- [17] For selected representative works, see: a) J. Legre, J. S. Gaynard, N. S. Robertson, H. F. Sore, M. Hyvönen, D. R. Spring, *Adv. Ther.* **2018**, *1*, 1800052; b) R. Hili, V. Rai, A. K. Yudin, *J. Am. Chem. Soc.* **2010**, *132*, 2889–2891; c) Á. Roxin, J. Chen, C. C. G. Scully, B. H. Rotstein, A. K. Yudin, G. Zheng, *Bioconjugate Chem.* **2012**, *23*, 1387–1395; d) A. V. Vasco, Y. Méndez, A. Porzel, J. Balbach, L. A. Wessjohann, D. G. Rivera, *Bioconjugate Chem.* **2019**, *30*, 253–259; e) C. M. Grison, G. M. Burslem, J. A. Miles, L. K. A. Pils, D. J. Yeo, Z. Imani, S. L. Warriner, M. E. Webb, A. J. Wilson, *Chem. Sci.* **2017**, *8*, 5166–5171; f) Y. Wu, A. Kaur, E. Fowler, M. M. Wiedmann, R. Young, W. R. J. D. Galloway, L. Olsen, H. F. Sore, A. Chattopadhyay, T. T.-L. Kwan, X. Xu, S. J. Walsh, P. de Andrade, M. Janecek, S. Arumugam, L. S. Itzhaki, Y. H. Lau, D. R. Spring, *ACS Chem. Biol.* **2019**, *14*, 526–533.

- [18] X. Ma, J. Kia, R. Cao, X. Wang, H. Fei, *J. Am. Chem. Soc.* **2014**, *136*, 17734–17737.
- [19] S. Ji, X. Yang, X. Chen, A. Li, D. Yan, H. Xu, H. Fei, *Chem. Sci.* **2020**, *11*, 9126–9133.
- [20] M. Todorovic, K. D. Schwab, J. Zeisler, C.-C. Zhang, F. Bénard, D. M. Perrin, *Angew. Chem. Int. Ed.* **2019**, *58*, 14120–14124; *Angew. Chem.* **2019**, *131*, 14258–14262.
- [21] L. Nevola, A. Martín-Quirós, K. Eckelt, N. Camarero, S. Tosi, A. Llobet, E. Giralt, P. Gorostiza, *Angew. Chem. Int. Ed.* **2013**, *52*, 7704–7708; *Angew. Chem.* **2013**, *125*, 7858–7862.
- [22] S. P. Brown, A. B. Smith III, *J. Am. Chem. Soc.* **2015**, *137*, 4034–4037.
- [23] S. Learte-Aymamí, C. Vidal, A. Gutiérrez-González, J. L. Mascareñas, *Angew. Chem. Int. Ed.* **2020**, *59*, 9149–9154; *Angew. Chem.* **2020**, *132*, 9234–9239.
- [24] Y. Wu, W.-S. Tam, H.-F. Chau, S. Kaur, W. Thor, W. S. Aik, W.-L. Chan, M. Zweckstetter, K.-L. Wong, *Chem. Sci.* **2020**, *11*, 11266–11273.
- [25] For a selected review, see: F. Danhier, A. Le Breton, V. Préat, *Mol. Pharm.* **2012**, *9*, 2961–2973.
- [26] M. D. Sachs, K. A. Rauen, M. Ramamurthy, J. L. Dodson, A. M. De Marzo, M. J. Putzi, M. P. Schoenberg, R. Rodriguez, *Urology* **2002**, *60*, 531–536.
- [27] J. Šimeček, J. Notni, T. G. Kapp, H. Kessler, H.-J. Wester, *Mol. Pharm.* **2014**, *11*, 1687–1695.
- [28] L. Mendive-Tapia, J. Wang, M. Vendrell, *Pept. Sci.* **2021**, *113*, e24181.
- [29] For a selected work, see: a) A. Schirer, Y. El Khoury, P. Faller, P. Hellwig, *JBIC J. Biol. Inorg. Chem.* **2017**, *22*, 581–589; b) P. Wang, S. Wang, L. Chen, W. Wang, B. Wang, Y. A. Liao, *Spectrochim. Acta Part A* **2020**, *240*, 118549; for a selected recent review, see: c) R. S. Singh, R. P. Paitandi, R. K. Gupta, D. S. Pandey, *Coord. Chem. Rev.* **2020**, *414*, 213269.
- [30] a) M. B. Berezin, E. V. Antina, G. B. Guseva, A. Y. Kritskaya, A. S. Semeikin, *Inorg. Chem. Commun.* **2020**, *111*, 107611; b) A. Al-Sheikh Ali, J. Cipot-Wechsler, T. S. Cameron, A. Thompson, *J. Org. Chem.* **2009**, *74*, 2866–2869.

Manuscript received: July 4, 2021

Accepted manuscript online: July 16, 2021

Version of record online: August 6, 2021